Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Key Ratios

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Key Ratios

Price & Volume

Recent Price $1.93
Recent Price 7/1/22
52 Week High $18.75
52 Week Low $1.80
5 Day Price Percent Change (%) 1.58%
4 Week Price Percent Change (%) -18.22%
26 Week Price Percent Change (%) -76.17%
52 Week Price Percent Change (%) -89.71%
Volume (3 Month Average) (Mil) 6.80
Volume (10 Day Average) (Mil) 0.06
Beta 2.30

Share Related Items

Market Capitalization (Mil) $13.70
Shares Outstanding (Mil) 7.10
Shares Outstanding, Average (FY) (Mil) 5.43
Float (Mil) 7.05

Dividend Information

Yield (%) --
Ex-Dividend Date
Dividend Rate --

Financial Strength

Quick Ratio (MRQ) --
Quick Ratio (FY)) --
Current Ratio (MRQ) 6.60
LT Debt to Equity (MRQ) (%) 12.75
LT Debt to Equity (MRQ) (%) 12.75
LT Debt to Equity (FY) (%) 10.49
Total Debt to Equity (MRQ) (%) 12.75
Total Debt to Equity (FY) (%) 10.49

Valuation Ratios

P/E (TTM) --
P/E (FY) --
P/E 5 Fiscal Year High --
P/E 5 Fiscal Year Low --
Price to Revenue (TTM) 27.40
Price to Revenue (MRQ) 27.33
Price to Revenue (FY) 27.40
Price to Cash Flow (TTM) --
Price to Cash Flow (MRQ) --
Price to Cash Flow (FY) --
Price to Free Cash Flow (TTM) --
Price to Free Cash Flow (FY) --
Price to Book (MRQ) 0.24
Price to Book (FY) 0.20
Price to Tangible Book (MRQ) 0.42
Price to Tangible Book (FY) 0.32
Price to Tangible Book - Common (MRQ) 0.89
Price to Tangible Book - Common (FY) 1.10

Per Share Data

Revenue/Share (TTM) $0.09
Revenue/Share (MRQ) $0.09
Revenue/Share (FY) $0.09
EPS Fully Diluted (TTM) $-4.43
EPS Fully Diluted (MRQ) $-1.82
Book Value/Share (MRQ) $8.02
Book Value/Share (FY) $9.67
Cash Flow/Share (TTM) $-4.32
Cash Flow/Share (MRQ) $-7.16
Cash Flow/Share (FY) $-3.70
Cash (MRQ) $7.16
Cash (FY) $8.56

Mgmt Effectiveness

Return on Equity (TTM) (%) -50.49
Return on Equity (MRQ) (%) -82.33
Return on Equity (FY) (%) -55.83
Return on Assets (TTM) (%) -37.20
Return on Assets (MRQ) (%) -60.72
Return on Assets (FY) (%) -37.23
Return on Investment (TTM) (%) -41.20
Return on Investment (MRQ) (%) -67.24
Return on Investment (FY) (%) -42.36

Profitability

Operating Margin (TTM) (%) -4,735.27
Operating Margin (MRQ) (%) -4,673.58
Operating Margin (FY) (%) -4,643.54
Net Profit Margin (TTM) (%) -5,110.92
Net Profit Margin (MRQ) (%) -8,379.46
Net Profit Margin (FY) (%) -4,153.85
Gross Margin (TTM) (%) --
Gross Margin (MRQ) (%) --
Gross Margin (FY) (%) --

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • LinkedIn
    • Twitter
    • RSS

Celsion
Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

LinkedIn

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2022 Celsion Corporation. All rights reserved.

    • Twitter
    • Facebook
    • LinkedIn
    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn